Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04642027

PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy

PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy of Biochemical Failure After Radical Prostatectomy for Prostate Cancer

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
538 (estimated)
Sponsor
University Medical Center Groningen · Academic / Other
Sex
Male
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years. The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT). sEBRT can provide long-term disease control; with 5 year biochemical progression-free survival (bPFS) up to 60% and with most treatment failures in the first 2 years after sEBRT. The main goal of this project is to investigate whether the oncologic outcome in patients with post-prostatectomy recurrent PCa can be improved, by increasing the biological effective radiation dose using a hypofractionated schedule of 20 x 3 = 60 Gy. The study is designed as a prospective open phase III randomized multicenter trial. All patients with biochemical recurrence with a PSA \< 1.0 ng/ml after radical prostatectomy for prostate cancer without evidence of lymph nodes or distance metastases will be included. PSA progression after prostatectomy defined as two consecutive rises with the final PSA \> 0.1 ng/mL or three consecutive rises will be included. All eligible patients will be randomized to one of the following two treatment arms: Arm 1 = Conventional sEBRT to apply a total dose of 70 Gy in 35 daily fractions of 2 Gy during 7 weeks. Arm 2 = Hypofractionated sEBRT to apply a total dose of 60 Gy in 20 fractions of 3 Gy during 4 weeks. The primary endpoint will be the 5-year progression-free survival (PFS) after treatment.

Conditions

Interventions

TypeNameDescription
RADIATIONConventional sEBRTA total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks
RADIATIONHypofractionated sEBRTA total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks

Timeline

Start date
2020-09-01
Primary completion
2029-09-01
Completion
2030-09-01
First posted
2020-11-24
Last updated
2024-02-28

Locations

13 sites across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT04642027. Inclusion in this directory is not an endorsement.